






Supplemental Figure S1.  
Determination of EC50 for NY-ESO-1-specific TCRs.  
(A and B) ELISA measuring secretion of IFN-γ from TCR-transduced PBMCs following 48 hours coincubation 
with K562 engineered to express HLA-A*02:01 and pulsed with varied concentrations of (A) MART26-35 or (B) 
NY157-165 peptide. (C-E) ELISA measuring secretion of IFN-γ from TCR-transduced PBMCs following 48 hours 
coincubation with K562 engineered to express (C) HLA-B*07:02, (D) HLA-B*18:01, or (E) HLA-C*03:04 and 
pulsed with varied concentrations of indicated peptides. Means ± SD for two technical replicates are shown. EC50 













Supplemental Figure S2.  
Establishment of xenograft tumor line and function of input T cells for in vivo experiment.  
(A) ELISA measuring secretion of IFN-γ from TCR-transduced PBMCs following 48 hours coincubation with 
derivatives of the PC-3 prostate cancer cell line engineered to express (left) HLA-A*02:01 and NY-ESO-1 full 
protein, (middle) HLA-A*02:01 alone, or (right) NY-ESO-1 full protein alone. Means ± SD for two technical 
replicates are shown. (B) ELISA comparing secretion of IFN-γ from TCR-transduced PBMCs following 48 hours 
coincubation with indicated M257 or PC-3 target cells. On the 4th day post-transduction, TCR-transduced PBMCs 
were sorted for CD3+/LNGFR+ and then expanded for 13 additional days prior to the co-culture/ELISA assay and 
the in vivo experiment. Means ± SD for a representative experiment with two technical replicates is shown. (C) 
Flow cytometry contour plots comparing the transduction (LNGFR+) levels of TCR-transduced PBMCs used for 
the in vivo experiment.  
 
